Abstract

Supporting self-management is key in improving disease control, with technology increasingly utilised. We hypothesised the addition of telehealth support following assessment in an integrated respiratory clinic could reduce unscheduled healthcare visits in patients with asthma and COPD. Following treatment optimisation, exacerbation-prone participants or those with difficulty in self-management were offered telehealth support. This comprised automated twice-weekly telephone calls, with a specialist nurse triaging alerts. We performed a matched cohort study assessing additional benefits of the telehealth service, matching by: confirmed diagnosis, age, sex, FEV1 percent predicted, smoking status and ≥1 exacerbation in the last year. Thirty-four telehealth participants were matched to twenty-nine control participants. The telehealth cohort generated 165 alerts, with 29 participants raising at least one alert; 88 (53.5%) alerts received a call discussing self-management, of which 35 (21%) received definitive advice that may otherwise have required an unscheduled healthcare visit. There was a greater reduction in median exacerbation rate across both telehealth groups at 6 months post-intervention (1 to 0, p < 0.001) but not in control groups (0.5 to 0.0, p = 0.121). Similarly, there was a significant reduction in unscheduled GP visits across the telehealth groups (1.5 to 0.0, p < 0.001), but not the control groups (0.5 to 0.0, p = 0.115). These reductions led to cost-savings across all groups, but greater in the telehealth cohorts. The addition of telehealth support to exacerbation-prone patients with asthma or COPD, following comprehensive assessment and treatment optimisation, proved beneficial in reducing exacerbation frequency and unscheduled healthcare visits and thus leads to significant cost-savings for the NHS.

Clinical Trial Registration: ClinicalTrials.gov: NCT03096509

Details

Title
Evaluation of telehealth support in an integrated respiratory clinic
Author
Fox, Lauren 1   VIAFID ORCID Logo  ; Heiden, Emily 1 ; Chauhan, Milan A. J. 1 ; Longstaff, Jayne M. 1 ; Balls, Lara 1 ; De Vos, Ruth 2 ; Neville, Daniel M. 2 ; Jones, Thomas L. 2   VIAFID ORCID Logo  ; Leung, Anthony W. 3 ; Morrison, Lydia 1 ; Rupani, Hitasha 2 ; Brown, Thomas P. 2 ; Stores, Rebecca 4 ; Chauhan, Anoop J. 5   VIAFID ORCID Logo 

 Portsmouth Hospitals University NHS Trust, Portsmouth Technology Trials Unit, Portsmouth, UK (GRID:grid.418709.3) (ISNI:0000 0004 0456 1761) 
 Portsmouth Hospitals University NHS Trust, Portsmouth Technology Trials Unit, Portsmouth, UK (GRID:grid.418709.3) (ISNI:0000 0004 0456 1761); Portsmouth Hospitals University NHS Trust, Respiratory Medicine, Portsmouth, UK (GRID:grid.418709.3) (ISNI:0000 0004 0456 1761) 
 Bordon Medical Centre, Bordon, UK (GRID:grid.418709.3) 
 University of Portsmouth, Faculty of Science and Health, Portsmouth, UK (GRID:grid.4701.2) (ISNI:0000 0001 0728 6636) 
 Portsmouth Hospitals University NHS Trust, Portsmouth Technology Trials Unit, Portsmouth, UK (GRID:grid.418709.3) (ISNI:0000 0004 0456 1761); Portsmouth Hospitals University NHS Trust, Respiratory Medicine, Portsmouth, UK (GRID:grid.418709.3) (ISNI:0000 0004 0456 1761); University of Portsmouth, Faculty of Science and Health, Portsmouth, UK (GRID:grid.4701.2) (ISNI:0000 0001 0728 6636) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20551010
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2735431383
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.